Core Viewpoint - Kubo Medical (02216) has seen a significant increase in stock price, rising over 9% during trading and currently up 5.86% at HKD 3.25, with a trading volume of HKD 11.79 million [1] Group 1: Company Actions - Kubo Medical announced plans to issue a total of 105 million subscription shares at a price of HKD 3.11 per share, representing a premium of approximately 1.3% over the previous trading day's closing price [1] - The net proceeds from this issuance are expected to be around HKD 327 million, which will be used for potential acquisitions in the medical device industry to continue expanding the product portfolio [1] - The company is actively seeking potential acquisition targets within the medical device sector and is currently in discussions with various parties [1] Group 2: Strategic Partnerships - Notably, Ying Tai Medical (01501) plans to invest approximately HKD 283 million to subscribe for about 91.09 million shares of Kubo Medical [1] - The announcement highlights that Kubo Medical has a rich product line in the non-vascular interventional field, and the subscription will further enhance the company's strategic positioning in this area [1]